that is so exciting. Alzheimer’s also runs in my family so if it can reverse or cure alzheimers that would be amazing also if it helps with the memory impairments and cognitive deficits in schizophrenia that would be amazing. This is giving me hope.
Drug is in phaae 1 so 10+ years until its available to the public. Its like karxt but better, it agonizes m1 and m4 but dosnt aagonize m2 m3 and m5. So you dont need an additional drug to antagonize the m2 m3 and m5, like you do with karxt
I came across a science paper, also dated to 10 days ago, and most likely related:
Background
Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator in development for the treatment of schizophrenia. We aimed to evaluate the safety and tolerability of multiple ascending doses of emraclidine in patients with schizophrenia.
Methods
We conducted a two-part, randomised, phase 1b trial in the USA. Eligible participants were aged 18–50 years (part A) or 18–55 years (part B) with a primary diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders 5th edition, as confirmed by the Mini International Neuropsychiatric Interview, and extrapyramidal symptom assessments indicating normal to mild symptoms at screening. Part A evaluated the safety and tolerability of emraclidine in five cohorts of participants with stable schizophrenia who received ascending oral doses of emraclidine 5–40 mg (40 mg was administered as 20 mg twice daily) or placebo at a single US site. Part B was a double-blind, randomised, placebo-controlled study that enrolled adults with acute schizophrenia across five US sites; participants were randomly assigned (1:1:1) to receive emraclidine 30 mg once daily, emraclidine 20 mg twice daily, or placebo for 6 weeks (doses established in part A). The primary endpoint was safety and tolerability, assessed in the safety population (participants who received at least one dose of emraclidine or placebo). This trial is now complete and is registered with ClinicalTrials.gov, NCT04136873.
Findings
Between Sept 23, 2019, and Sept 17, 2020, 118 patients were assessed for eligibility and 49 were randomly assigned across five cohorts in part A. 44 participants completed the study, with 36 participants receiving emraclidine and eight receiving placebo. The two highest doses tested were selected for part B. Between Oct 12, 2020, and May 7, 2021, 148 patients were assessed for eligibility and 81 were randomly assigned to emraclidine 30 mg once daily (n=27), emraclidine 20 mg twice daily (n=27), or placebo (n=27) in part B. Incidence of adverse events (14 [52%] of 27 participants in the emraclidine 30 mg once daily group, 15 [56%] of 27 in the emraclidine 20 mg twice daily group, and 14 [52%] of 27 in the placebo group), clinical assessments, and weight changes were similar across groups. The most common adverse event was headache (15 [28%] of 54 participants in the emraclidine groups, seven [26%] of 27 in the placebo group). Modest, transient increases in blood pressure and heart rate in emraclidine groups observed at treatment initiation diminished over time and were not considered clinically meaningful by week 6.
Interpretation
These data support further investigation of emraclidine as a once-daily treatment for schizophrenia without need for titration and with a potentially favourable side-effect profile.
Funding
Cerevel Therapeutics.
I think it is too early to say anything about the med if it is in phase 1 trial.
Do you know which medications are in phase 3 trial currently?
KarXT, ulotaront and brilaroxazine are in phase 3 USA.
brilaroxazine is like Abilify or Vraylar from what I read. What makes it different?
Are there any other medications currently in phase 3 trial?
Pesamptor is close
I see no phase 3 trials for PF-04958242 / pesamptor.
This is a search of phase 3 clinical trials. It found some other meds for cognition, T.D. etc. Mentioned Nuplazid / pimavanserin trial for negatives.
It just finished 2b so it’s the closest out all the cognitive enhancers
Wait may still be in phase 2.
Also, NaBen is in phase 3 as an add on. Estimated trial completion late 2024.
Curiously, I started googling NaBen, recalled that it’s Sodium Benzoate, and then discovered that a product titled “Caffeine Sodium Benzoate” (Кофеин-бензоат натрия 100 мг) is sold in a local pharmacy at a cheap price, although it’s unclear how much sodium benzoate it contains.
It is touted to help people who are suffering from “decreased physical and mental capacity”.
As for NaBen, I found this phase III study with completion dates in late 2006.